Literature DB >> 17327353

Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease.

Keith G Tolman1, Vivian Fonseca, Anthony Dalpiaz, Meng H Tan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17327353     DOI： 10.2337/dc06-1539

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  142 in total

1.  73-year-old man with increasing abdominal girth and dyspnea.

Authors:  Sara L Reppert; Christopher M Wittich
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

2.  The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.

Authors:  Reona Morio; Hideyuki Hyogo; Masahiro Hatooka; Kei Morio; Hiromi Kan; Tomoki Kobayashi; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hiroshi Aikata; Hidenori Ochi; Yoneda Masayasu; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2016-06-28       Impact factor: 7.527

3.  A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes.

Authors:  Shuai Xue; Jianli Yin; Jiawei Shao; Yuanhuan Yu; Linfeng Yang; Yidan Wang; Mingqi Xie; Martin Fussenegger; Haifeng Ye
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

4.  Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation.

Authors:  Quan Zhang; Yan Li; Tingting Liang; Xuemian Lu; Xingkai Liu; Chi Zhang; Xin Jiang; Robert C Martin; Mingliang Cheng; Lu Cai
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 5.  The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus.

Authors:  Shazia Hussain; Tahseen A Chowdhury
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 6.  Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

Review 7.  Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.

Authors:  Diego Garcia-Compean; Joel Omar Jaquez-Quintana; Jose Alberto Gonzalez-Gonzalez; Hector Maldonado-Garza
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

8.  Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Michel Chonchol; Lorenzo Bertolini; Stefano Rodella; Luciano Zenari; Giuseppe Lippi; Massimo Franchini; Giacomo Zoppini; Michele Muggeo
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

Review 9.  Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination.

Authors:  Rudruidee Karnchanasorn; Horng-Yih Ou; James Lin; Lee-Ming Chuang; Ken C Chiu
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

10.  Usefulness of ultrasonographic estimation of preperitoneal and subcutaneous fat thickness in the diagnosis of nonalcoholic fatty liver disease in diabetic patients.

Authors:  Kazuto Fukuda; Yasushi Seki; Masahiro Ichihi; Takuya Okada; Ayumu Hirata; Sachiyo Kogita; Yoshiyuki Sawai; Takumi Igura; Mamiko Tsugawa; Yasuharu Imai
Journal:  J Med Ultrason (2001)       Date:  2015-02-11       Impact factor: 1.314
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.